Postoperative IMRT to reduce recurrence in early glottic cancer involving the anterior commissure
Official title: Role of Postoperative Radiotherapy in T1-T2N0M0 Glottic Carcinoma Involving the Anterior Commissure: A Prospective, Multicenter, Phase II Clinical Trial
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07781085 · Data updated 2026-11-12
This trial tests whether adding postoperative IMRT after surgery for early-stage glottic cancer with anterior commissure involvement can lower local recurrence.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 38 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | September 16, 2026 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT07781085 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with pathologically confirmed early-stage glottic cancer involving the anterior commissure who had curative surgery with negative margins 4–8 weeks prior and no prior radiotherapy or chemotherapy.
✕Probably not a fit
Patients without anterior commissure involvement, with positive margins, or who have had prior head and neck radiotherapy or systemic treatment may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, prospective, single-arm phase II study evaluates intensity modulated radiotherapy after curative surgery in adults with T1-T2N0M0 glottic squamous cell carcinoma involving the anterior commissure. Eligible patients have negative surgical margins and are within 4–8 weeks post-operation, with no prior radiotherapy or systemic treatment. The aim is to see if postoperative IMRT improves local control and long-term survival compared with historical expectations for this subgroup. The study is conducted at a single lead center in Hangzhou, China, with strict eligibility criteria including performance status 0-1 and informed consent.
Why it matters
Potential benefit: If successful, patients may have a lower risk of local recurrence and potentially better long-term control of the disease.
How similar studies have gone: Previous approaches using radiotherapy or surgical options show variable control for anterior commissure involvement; this remains a relatively niche, unanswered area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 years or older, regardless of gender; 2. Pathologically confirmed glottic squamous cell carcinoma; 3. T1-T2N0M0 glottic laryngeal carcinoma with anterior commissure involvement; 4. Patients who have undergone curative intent surgery for glottic carcinoma with negative surgical margins, within 4-8 weeks post operation; 5. No prior radiotherapy, chemotherapy or other anti neoplastic agent treatment; 6. ECOG performance status of 0 or 1; 7. Signed informed consent form. Exclusion Criteria: 1. Patients without anterior commissure involvement; 2. Prior chemotherapy or treatment with other anti neoplastic agents; 3. Prior history of head and neck radiotherapy; 4. Prior participation in other clinical trials; 5. Patients with severe allergy history or allergic diathesis, e.g., contrast medium allergy; 6. Pregnant or lactating women; 7. Patients with uncontrolled acute infection; 8. Patients with drug addiction, substance abuse, chronic heavy alcohol consumption, or human immunodeficiency virus (HIV) infection; 9. Patients with other uncontrolled concurrent malignancies.
Where it's running
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Dongjun Dai, Doctor
- Email: daidongjunmed@zju.edu.cn
- Phone: 86-0571-86992821
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.